Most acute and early-onset NT is believed to be caused by immune effector cell–associated NT syndrome (ICANS), which is a well-described entity with CD-19 CAR T-cell therapies for non-Hodgkin’s lymphoma or B-cell acute lymphoblastic leukemia [53,54]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.